The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery

Richard S E Keefe, Terry E. Goldberg, Philip D Harvey, James M. Gold, Margaret P. Poe, Leigh Coughenour

Research output: Contribution to journalArticle

707 Citations (Scopus)

Abstract

Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. Compared to healthy controls matched for age and parental education, patients with schizophrenia performed 1.49 standard deviations lower on a composite score calculated from the BACS and 1.61 standard deviations lower on a composite score calculated from the standard battery. The BACS composite scores were highly correlated with the standard battery composite scores in patients (r=0.76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement.

Original languageEnglish
Pages (from-to)283-297
Number of pages15
JournalSchizophrenia Research
Volume68
Issue number2-3
DOIs
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Cognition
Schizophrenia
Clinical Trials
Patient Education
Psychometrics
Parents

Keywords

  • BACS
  • Neurocognitive assessment batteries
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

The Brief Assessment of Cognition in Schizophrenia : Reliability, sensitivity, and comparison with a standard neurocognitive battery. / Keefe, Richard S E; Goldberg, Terry E.; Harvey, Philip D; Gold, James M.; Poe, Margaret P.; Coughenour, Leigh.

In: Schizophrenia Research, Vol. 68, No. 2-3, 01.06.2004, p. 283-297.

Research output: Contribution to journalArticle

Keefe, Richard S E ; Goldberg, Terry E. ; Harvey, Philip D ; Gold, James M. ; Poe, Margaret P. ; Coughenour, Leigh. / The Brief Assessment of Cognition in Schizophrenia : Reliability, sensitivity, and comparison with a standard neurocognitive battery. In: Schizophrenia Research. 2004 ; Vol. 68, No. 2-3. pp. 283-297.
@article{a4e143efab1a4dfa9ddd75071e4ec2f2,
title = "The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery",
abstract = "Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. Compared to healthy controls matched for age and parental education, patients with schizophrenia performed 1.49 standard deviations lower on a composite score calculated from the BACS and 1.61 standard deviations lower on a composite score calculated from the standard battery. The BACS composite scores were highly correlated with the standard battery composite scores in patients (r=0.76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement.",
keywords = "BACS, Neurocognitive assessment batteries, Schizophrenia",
author = "Keefe, {Richard S E} and Goldberg, {Terry E.} and Harvey, {Philip D} and Gold, {James M.} and Poe, {Margaret P.} and Leigh Coughenour",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.schres.2003.09.011",
language = "English",
volume = "68",
pages = "283--297",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - The Brief Assessment of Cognition in Schizophrenia

T2 - Reliability, sensitivity, and comparison with a standard neurocognitive battery

AU - Keefe, Richard S E

AU - Goldberg, Terry E.

AU - Harvey, Philip D

AU - Gold, James M.

AU - Poe, Margaret P.

AU - Coughenour, Leigh

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. Compared to healthy controls matched for age and parental education, patients with schizophrenia performed 1.49 standard deviations lower on a composite score calculated from the BACS and 1.61 standard deviations lower on a composite score calculated from the standard battery. The BACS composite scores were highly correlated with the standard battery composite scores in patients (r=0.76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement.

AB - Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. Compared to healthy controls matched for age and parental education, patients with schizophrenia performed 1.49 standard deviations lower on a composite score calculated from the BACS and 1.61 standard deviations lower on a composite score calculated from the standard battery. The BACS composite scores were highly correlated with the standard battery composite scores in patients (r=0.76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement.

KW - BACS

KW - Neurocognitive assessment batteries

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=1942536959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942536959&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2003.09.011

DO - 10.1016/j.schres.2003.09.011

M3 - Article

C2 - 15099610

AN - SCOPUS:1942536959

VL - 68

SP - 283

EP - 297

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -